Related Experiment Video
Updated: May 18, 2026
06:29
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders
1Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy. amrisita@unina.it
Immunobiology
|September 12, 2012
Summary
Eculizumab, a complement inhibitor, effectively treats paroxysmal nocturnal hemoglobinuria (PNH) by reducing complement-mediated hemolysis. This success drives research into new complement inhibitors for PNH and other related diseases.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder caused by complement dysregulation, leading to intravascular hemolysis.
- PNH erythrocytes lack complement regulators CD55 and CD59, making them susceptible to complement-mediated damage.
- Eculizumab, a C5 inhibitor, has shown significant clinical benefit in treating PNH by controlling hemolysis.
Purpose of the Study:
- To review PNH as a disease model for complement inhibition.
- To discuss the development of novel complement modulators based on PNH insights.
- To explore other hemolytic disorders as candidates for complement inhibition.
Main Methods:
- Review of existing literature on PNH and complement inhibition.
- Analysis of eculizumab's mechanism and clinical outcomes in PNH.
- Discussion of emerging complement inhibition strategies and potential therapeutic targets.
Main Results:
- Eculizumab effectively inhibits complement-mediated intravascular hemolysis in PNH.
- Understanding complement system modulation by eculizumab has advanced.
- New generations of complement inhibitors targeting different cascade steps are under development.
Conclusions:
- PNH serves as a crucial model for understanding and developing complement inhibitors.
- Eculizumab's success has expanded the scope of complement inhibition to other diseases.
- Further research into novel complement modulators holds promise for treating various complement-mediated disorders.
Related Concept Videos
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:01Hypersensitivity Reactions: Cytolytic Reactions
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
01:27Disorders of Erythrocytes
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:27Complement System
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
02:45Blood Transfusion and Agglutination
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:36Humoral Immune Responses
Overview